sábado, 14 de novembro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 5, 2026

Human Vaccines Market Size to Reach USD 62.45 Billion by 2033, Driven by Expanding Immunization Programs – SNS Insider

View original at globenewswire.com
Human Vaccines Market Size to Reach USD 62.45 Billion by 2033, Driven by Expanding Immunization Programs – SNS Insider Austin, United States, Feb…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • COVID-19 vaccines dominated with a 31.25% share in 2025

    80% confidence

  • Research & Academic Institutes are forecasted to register the fastest CAGR of 7.21% during 2026–2033

    80% confidence

  • Intradermal delivery is projected to expand at the fastest CAGR of 6.45% during the forecast period

    80% confidence

  • Intramuscular vaccines accounted for the highest market share of 46.32% in 2025

    80% confidence

  • North America dominated the Human Vaccines Market, accounting for a 34.56% market share in 2025

    80% confidence

  • The U.S. Human Vaccines Market is expected to grow from USD 11.72 billion in 2025 to USD 15.17 billion by 2033, registering a CAGR of 3.30% during the forecast period

    80% confidence

  • The Human Vaccines Market size was valued at USD 44.26 billion in 2025 and is expected to reach USD 62.45 billion by 2033, growing at a CAGR of 4.43% during the forecast period of 2026-2033

    80% confidence

  • Hospitals accounted for the largest share of 53.12% in 2025

    80% confidence

  • The Human Vaccines Market is driven by the rising awareness of preventive healthcare, expansion of national immunization programs, and rising cases of infectious and chronic diseases

    80% confidence

  • Online Pharmacy is expected to grow at the fastest CAGR of 6.78% during 2026–2033

    80% confidence

  • mRNA vaccines are expected to grow at the fastest CAGR of 7.12% during 2026–2033

    80% confidence

  • The market is challenged by high development costs, complex manufacturing processes, and strict regulatory requirements

    80% confidence

  • The Asia Pacific Human Vaccines Market is the fastest-growing globally, projected to register a CAGR of 5.89% during 2026–2033

    80% confidence

  • Hospital Pharmacy held the largest share of 45.87% in 2025

    80% confidence

  • Adult vaccines held the largest share of 39.61% in 2025

    80% confidence

  • Geriatric vaccines are expected to grow at the fastest CAGR of 6.98% during 2026–2033

    80% confidence

  • HPV vaccines are anticipated to record the fastest CAGR of 7.34% through 2026–2033

    80% confidence

  • Inactivated vaccines held the largest market share of 28.74% in 2025

    80% confidence

  • Government vaccination programs are an essential factor in the development of the market

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,577 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Human Vaccines Market Size to Reach USD 62.45 Billion by 2033, Driven by Expanding Immunization Programs – SNS Insider — Source | Via News | pt.VIA.NEWS